Gilead CEO Daniel O'Day (Jim Watson/AFP via Getty Images)
Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year
Gilead Sciences notched “fine” sales for the first quarter but the biopharma promised more to come.
Gilead reported sales of $6.6 billion, a 5% increase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
